Abstract:Influenza A virus (IAV) is well known for its pandemic potential. While current surveillance and vaccination strategies are highly effective, therapeutic approaches are often short-lived due to the high mutation rates of IAV. Recently, monoclonal antibodies (mAbs) have emerged as a promising therapeutic approach, both against current strains and future IAV pandemics. In addition to mAbs, several antibody-like alternatives exist, which aim to improve upon mAbs. Among these, Affimers stand out for their short development time, high expression levels in Escherichia coli, and animal-free production. In this study, we utilized the Affimer platform to isolate and produce specific and potent inhibitors of IAV. Using a monomeric version of the IAV trimeric hemagglutinin (HA) fusion protein, we isolated 12 Affimers that inhibit IAV infection in vitro. Two of these Affimers were characterized in detail and exhibited nanomolar-binding affinities to the target H3 HA protein, specifically binding to the HA1 head domain. Cryo-electron microscopy (cryo-EM), employing a novel spray approach to prepare cryo-grids, allowed us to image HA-Affimer complexes. Combined with functional assays, we determined that these Affimers inhibit IAV by blocking the interaction of HA with the host-cell receptor, sialic acid. Furthermore, these Affimers inhibited IAV strains closely related to the one used for their isolation. Overall, our results support the use of Affimers as a viable alternative to existing targeted therapies for IAV and highlight their potential as diagnostic reagents. Importance: Influenza A virus is one of the few viruses that can cause devastating pandemics. Due to the high mutation rates of this virus, annual vaccination is required, and antivirals are short-lived. Monoclonal antibodies present a promising approach to tackle influenza virus infections but are associated with some limitations. To improve on this strategy, we explored the Affimer platform, which are antibody-like proteins made in bacteria. By performing phage-display against a monomeric version of influenza virus fusion protein, an established viral target, we were able to isolate Affimers that inhibit influenza virus infection in vitro. We characterized the mechanism of inhibition of the Affimers by using assays targeting different stages of the viral replication cycle. We additionally characterized HA-Affimer complex structure, using a novel approach to prepare samples for cryo-electron microscopy. Overall, these results show that Affimers are a promising tool against influenza virus infection.

A Universal Aptamer for Influenza A Viruses: Selection, Recognition, and Infection Inhibition.

A Dna Aptamer Against Influenza A Virus: an Effective Inhibitor to the Hemagglutinin-Glycan Interactions

Aptamers to Hemagglutinin: A Novel Tool for Influenza Virus Recognition and Neutralization.

Two DNA Aptamers Against Avian Influenza H9N2 Virus Prevent Viral Infection in Cells.

Highly-Efficient Selection of Aptamers for Quantitative Fluorescence Detecting Multiple IAV Subtypes

Potent Inhibition of Human Influenza H5n1 Virus by Oligonucleotides Derived by Selex

Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice

Two Escape Mechanisms of Influenza A Virus to A Broadly Neutralizing Stalk-Binding Antibody

Identification and Structural Characterization of a Broadly Neutralizing Antibody Targeting a Novel Conserved Epitope on the Influenza Virus H5N1 Hemagglutinin

Exploiting the Affimer platform against influenza A virus

Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Molecular Docking of Broad-Spectrum Antibodies on Hemagglutinins of Influenza A Virus

Identification of a universal antigen epitope of influenza A virus using peptide microarray

Characterization of Potent Fusion Inhibitors of Influenza Virus

Development and Characterization of an Antibody That Recognizes Influenza Virus N1 Neuraminidases

Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies

Identification of a Novel Inhibitor Targeting Influenza A Virus Group 2 Hemagglutinins.

Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in hemagglutinin globular head

Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus

Potent sialic acid inhibitors that target influenza A virus hemagglutinin